ConductScience.org, home

Paper455325

Experimental evaluation of anthracycline analogs.

Casazza AM. Cancer Treat Rep, 1979. Cited by 196 papers, by iCite.

Cite this record

ConductScience Library. Experimental evaluation of anthracycline analogs. Papers, record 455325. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/455325

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Experimental evaluation of anthracycline analogs.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
196
iCite
Relative citation ratio, by iCite
10.9
iCite
Revised in PubMed
2013-11-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Casazza AMA M

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
NaphthacenesMajor topic
Neoplasms, ExperimentalMajor topic
Animals
Daunorubicin
Disease Models, Animal
Doxorubicin
Drug Administration Schedule
Drug Evaluation, Preclinical
Glycosides
HeLa Cells
Heart
Leukemia L1210
Leukemia, Experimental
Mice
Sarcoma, Experimental

Source PubMed

Download CSV of topics

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 196 citations.

PMIDTitleJournalYearIn PapersSource
36551106Preparation of a Highly Sensitive Electrochemical Aptasensor for Measuring Epirubicin Based on a Gold Electrode Boosted with Carbon Nano-Onions and MB.Biosensors (Basel)2022https://conductscience.org/library/papers/36551106PubMed
31807919Cerium-doped flower-shaped ZnO nano-crystallites as a sensing component for simultaneous electrochemical determination of epirubicin and methotrexate.Mikrochim Acta2019https://conductscience.org/library/papers/31807919PubMed
24277182Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.Pharm Res1984https://conductscience.org/library/papers/24277182PubMed
16107896Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.Leukemia2005https://conductscience.org/library/papers/16107896PubMed
9330607Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.Jpn J Cancer Res1997https://conductscience.org/library/papers/9330607PubMed
8070217Clinical pharmacokinetics of epirubicin.Clin Pharmacokinet1994https://conductscience.org/library/papers/8070217PubMed
8043941Potential role of oral anthracyclines in older patients with cancer.Drugs Aging1994https://conductscience.org/library/papers/8043941PubMed
7693418Epirubicin. Clinical pharmacology and dose-effect relationship.Drugs1993https://conductscience.org/library/papers/7693418PubMed
6946877Evaluation of new anthracycline analogs with the human tumor stem cell assay.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/6946877PubMed
6940195Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6940195PubMed
6831630Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6831630PubMed
6678877Phase I trial with 4'-deoxydoxorubicin (esorubicin).Invest New Drugs1983https://conductscience.org/library/papers/6678877PubMed
6595240Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.Invest New Drugs1984https://conductscience.org/library/papers/6595240PubMed
6590530Phase I study of 4-demethoxydaunorubicin.Invest New Drugs1983https://conductscience.org/library/papers/6590530PubMed
6590528Pharmacokinetics of 4'-epi-doxorubicin in man.Invest New Drugs1983https://conductscience.org/library/papers/6590528PubMed
65832054'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6583205PubMed
6579052Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.J Cancer Res Clin Oncol1983https://conductscience.org/library/papers/6579052PubMed
6511232Phase II study of carminomycin in a human tumor cloning assay.Invest New Drugs1984https://conductscience.org/library/papers/6511232PubMed
3863718Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3863718PubMed
3859341Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.Blut1985https://conductscience.org/library/papers/3859341PubMed

See all 46 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/455325

GET https://conductscience.org/api/papers/v1/455325/cited_by?page=2